Details of the Drug Combination

General Information of Drug Combination (ID: DCUMAK5)

• Drug Combination Name: Gemcitabine + Paclitaxel
• Indication: Head and Neck Cancer; Status: Phase 1 [1]
• Component Drugs:
  Gemcitabine (DMSE3I7): Small molecular drug
  Paclitaxel (DMLB81S): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Gemcitabine

Disease Entry	ICD 11	Status	REF
Anterior urethra cancer	N.A.	Approved	[2]
Biliary tract cancer	2C17	Approved	[2]
Carcinoma	2A00-2F9Z	Approved	[2]
Cervical cancer	2C77.0	Approved	[2]
Cholangiocarcinoma	2C12.10	Approved	[2]
Fallopian tube neoplasm	N.A.	Approved	[2]
Gallbladder carcinoma	N.A.	Approved	[2]
Leiomyosarcoma	2B58	Approved	[2]
Leukemia	N.A.	Approved	[2]
Lung cancer	2C25.0	Approved	[2]
MALT lymphoma	N.A.	Approved	[2]
Nodal marginal zone lymphoma	2A85.0	Approved	[2]
Non-small-cell lung cancer	2C25	Approved	[3]
Ovarian disorder	N.A.	Approved	[2]
Ovarian neoplasm	N.A.	Approved	[2]
Pancreatic adenocarcinoma	N.A.	Approved	[2]
Pancreatic ductal carcinoma	2C10.0	Approved	[2]
Pancreatic tumour	2C10	Approved	[2]
Posterior urethra cancer	N.A.	Approved	[2]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Splenic marginal zone lymphoma	N.A.	Approved	[2]
Urethral cancer	2C93	Approved	[2]
Urinary bladder neoplasm	N.A.	Approved	[2]
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[5]
Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[5]
Colon cancer	2B90.Z	Investigative	[2]

Gemcitabine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ribonucleoside-diphosphate reductase M2 (RRM2)	TTBWDI0	RIR2_HUMAN	Modulator	[13]

Gemcitabine Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]
Multidrug resistance-associated protein 5 (ABCC5)	DTYVM24	MRP5_HUMAN	Substrate	[15]
Concentrative nucleoside transporter 1 (SLC28A1)	DT0EQPW	S28A1_HUMAN	Substrate	[16]

Gemcitabine Interacts with 5 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytidine aminohydrolase (CDA)	DEKEDRC	CDD_HUMAN	Metabolism	[17]
Uridine/cytidine monophosphate kinase (UMPK)	DEMPH4I	KCY_HUMAN	Metabolism	[18]
Cytidine deaminase (cdd)	DETX3A5	CDD_ECOLI	Metabolism	[19]
Cytidine deaminase (cdd)	DEFVABT	CDD_KLEP7	Metabolism	[19]
Cytidine deaminase (cdd)	DEYILK4	E0TLJ6_MYCHH	Metabolism	[20]

Gemcitabine Interacts with 244 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytidine deaminase (CDA)	OT3HXP6N	CDD_HUMAN	Affects Response To Substance	[11]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Expression	[21]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2)	OTOB6J6R	RIR2_HUMAN	Affects Response To Substance	[12]
Ribonucleoside-diphosphate reductase large subunit (RRM1)	OTXGQOR9	RIR1_HUMAN	Affects Response To Substance	[12]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[22]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Expression	[23]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[24]
NF-kappa-B inhibitor epsilon (NFKBIE)	OTLAYEL9	IKBE_HUMAN	Affects Expression	[7]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B)	OTQ4W7MT	TR11B_HUMAN	Increases Expression	[7]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Increases Expression	[7]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Decreases Expression	[7]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Increases Expression	[7]
E3 ubiquitin-protein ligase Praja-2 (PJA2)	OT45TMC4	PJA2_HUMAN	Increases Expression	[7]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2)	OT6Y1QZN	IRAK2_HUMAN	Increases Expression	[7]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Expression	[7]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L)	OTJKOMXE	BNI3L_HUMAN	Increases Expression	[7]
Heterogeneous nuclear ribonucleoprotein Q (SYNCRIP)	OTRNDZXB	HNRPQ_HUMAN	Decreases Expression	[7]
Melanoma-associated antigen C1 (MAGEC1)	OTHMFHH8	MAGC1_HUMAN	Increases Expression	[7]
Liprin-alpha-4 (PPFIA4)	OTWXG0DO	LIPA4_HUMAN	Increases Expression	[7]
Transcription factor Maf (MAF)	OT1GR3IZ	MAF_HUMAN	Increases Expression	[7]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[7]
Krueppel-like factor 8 (KLF8)	OTUC5CDB	KLF8_HUMAN	Increases Expression	[7]
Urokinase-type plasminogen activator (PLAU)	OTX0QGKK	UROK_HUMAN	Increases Expression	[7]
Fibrinogen gamma chain (FGG)	OT5BJSEX	FIBG_HUMAN	Affects Expression	[7]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[7]
Keratin, type II cytoskeletal 8 (KRT8)	OTTM4X11	K2C8_HUMAN	Decreases Expression	[7]
Growth-regulated alpha protein (CXCL1)	OT3WCTZV	GROA_HUMAN	Increases Expression	[7]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)	OTXOQDSG	IFIT1_HUMAN	Increases Expression	[7]
Transcriptional activator Myb (MYB)	OTJH64IV	MYB_HUMAN	Increases Expression	[7]
Osteopontin (SPP1)	OTJGC23Y	OSTP_HUMAN	Increases Expression	[7]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Increases Expression	[7]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)	OT2HZK5M	GTR3_HUMAN	Increases Expression	[7]
Creatine kinase B-type (CKB)	OTUCKOTT	KCRB_HUMAN	Decreases Expression	[7]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[7]
Homeobox protein Hox-B2 (HOXB2)	OTTD6HMV	HXB2_HUMAN	Increases Expression	[7]
Fos-related antigen 2 (FOSL2)	OT3MT9HJ	FOSL2_HUMAN	Decreases Expression	[7]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Decreases Expression	[7]
CCAAT/enhancer-binding protein beta (CEBPB)	OTM9MQIA	CEBPB_HUMAN	Increases Expression	[7]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Increases Expression	[7]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[7]
C-X-C motif chemokine 2 (CXCL2)	OTEJCYMY	CXCL2_HUMAN	Increases Expression	[7]
C-X-C motif chemokine 3 (CXCL3)	OTSL94KH	CXCL3_HUMAN	Increases Expression	[7]
Endothelin-2 (EDN2)	OTQ7RCPI	EDN2_HUMAN	Decreases Expression	[7]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3)	OTVLI4DD	TNAP3_HUMAN	Increases Expression	[7]
Diamine acetyltransferase 1 (SAT1)	OT52AU22	SAT1_HUMAN	Increases Expression	[7]
Prostaglandin G/H synthase 1 (PTGS1)	OTHCRLEC	PGH1_HUMAN	Decreases Expression	[7]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[7]
Tumor necrosis factor receptor superfamily member 5 (CD40)	OT5YU2XB	TNR5_HUMAN	Decreases Expression	[7]
Myristoylated alanine-rich C-kinase substrate (MARCKS)	OT7N056G	MARCS_HUMAN	Increases Expression	[7]
Protein EVI2B (EVI2B)	OT98X1OE	EVI2B_HUMAN	Decreases Expression	[7]
Heat shock 70 kDa protein 1-like (HSPA1L)	OTC2V1K6	HS71L_HUMAN	Decreases Expression	[7]
Glutaredoxin-1 (GLRX)	OT0QHTAR	GLRX1_HUMAN	Increases Expression	[7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[7]
Nicotinamide N-methyltransferase (NNMT)	OTFM38GU	NNMT_HUMAN	Increases Expression	[7]
B-cell lymphoma 6 protein (BCL6)	OTQAWWO1	BCL6_HUMAN	Increases Expression	[7]
Regulator of G-protein signaling 2 (RGS2)	OT0FSRW7	RGS2_HUMAN	Increases Expression	[7]
Leukemia inhibitory factor receptor (LIFR)	OT36W9O5	LIFR_HUMAN	Increases Expression	[7]
Melanoma-associated antigen 10 (MAGEA10)	OTI4KPYB	MAGAA_HUMAN	Decreases Expression	[7]
Lysophosphatidic acid receptor 6 (LPAR6)	OT4BY3W4	LPAR6_HUMAN	Decreases Expression	[7]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1)	OTZRWTGA	IQGA1_HUMAN	Increases Expression	[7]
Retinaldehyde dehydrogenase 3 (ALDH1A3)	OT1C9NKQ	AL1A3_HUMAN	Increases Expression	[7]
Max-interacting protein 1 (MXI1)	OTUQ9E0D	MXI1_HUMAN	Increases Expression	[7]
ETS translocation variant 1 (ETV1)	OT6PMJIK	ETV1_HUMAN	Increases Expression	[7]
Glypican-3 (GPC3)	OTWS8WSW	GPC3_HUMAN	Increases Expression	[7]
Transcription initiation factor IIA subunit 1 (GTF2A1)	OTWW4PN0	TF2AA_HUMAN	Affects Expression	[7]
Growth arrest-specific protein 1 (GAS1)	OTKJXG52	GAS1_HUMAN	Decreases Expression	[7]
Puromycin-sensitive aminopeptidase (NPEPPS)	OTMENFXR	PSA_HUMAN	Decreases Expression	[7]
Methionine--tRNA ligase, cytoplasmic (MARS1)	OTLJ6MHJ	SYMC_HUMAN	Increases Expression	[7]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Affects Expression	[7]
Ras-related protein Rab-8A (RAB8A)	OTPB54Y3	RAB8A_HUMAN	Decreases Expression	[7]
Lysozyme C (LYZ)	OTD7H0G6	LYSC_HUMAN	Decreases Expression	[7]
Transforming growth factor beta-2 proprotein (TGFB2)	OTC0TXEP	TGFB2_HUMAN	Increases Expression	[7]
Large ribosomal subunit protein eL37 (RPL37)	OTB6SDZ1	RL37_HUMAN	Increases Expression	[7]
Histone H4 (H4C1)	OTB71W46	H4_HUMAN	Decreases Expression	[7]
C-C motif chemokine 20 (CCL20)	OTUCJY4N	CCL20_HUMAN	Increases Expression	[7]
ADP-ribosylation factor 1 (ARF1)	OT5C4C3L	ARF1_HUMAN	Decreases Expression	[7]
Nuclear factor NF-kappa-B p100 subunit (NFKB2)	OTS231V7	NFKB2_HUMAN	Affects Expression	[7]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1)	OT8LCZCT	MMSA_HUMAN	Increases Expression	[7]
Pro-neuregulin-1, membrane-bound isoform (NRG1)	OTZO6F1X	NRG1_HUMAN	Increases Expression	[7]
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11)	OTFH9M73	PTN11_HUMAN	Affects Expression	[7]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Decreases Expression	[7]
ATP-dependent RNA helicase A (DHX9)	OT5AAOQI	DHX9_HUMAN	Decreases Expression	[7]
Nuclear cap-binding protein subunit 1 (NCBP1)	OTYBR927	NCBP1_HUMAN	Increases Expression	[7]
TP53-binding protein 1 (TP53BP1)	OTL8879S	TP53B_HUMAN	Increases Expression	[7]
Ankyrin-3 (ANK3)	OTJ3IRBP	ANK3_HUMAN	Increases Expression	[7]
TNF receptor-associated factor 1 (TRAF1)	OTTLM5RU	TRAF1_HUMAN	Affects Expression	[7]
PDZK1-interacting protein 1 (PDZK1IP1)	OTWA6M5K	PDZ1I_HUMAN	Increases Expression	[7]
Treacle protein (TCOF1)	OT4BOYTM	TCOF_HUMAN	Decreases Expression	[7]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Affects Expression	[7]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Increases Expression	[7]
Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1)	OTD1KRKO	DYHC1_HUMAN	Decreases Expression	[7]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Increases Expression	[7]
Interferon regulatory factor 3 (IRF3)	OT81U8ME	IRF3_HUMAN	Decreases Expression	[7]
FXYD domain-containing ion transport regulator 3 (FXYD3)	OT9PPRHE	FXYD3_HUMAN	Increases Expression	[7]
Ankyrin repeat domain-containing protein 1 (ANKRD1)	OTHJ7JV9	ANKR1_HUMAN	Increases Expression	[7]
Disks large homolog 2 (DLG2)	OTQ3BD8U	DLG2_HUMAN	Increases Expression	[7]
Cysteine and glycine-rich protein 2 (CSRP2)	OT4SW0HI	CSRP2_HUMAN	Increases Expression	[7]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Increases Expression	[7]
Golgi-associated kinase 1B (GASK1B)	OT2HPHEI	GAK1B_HUMAN	Decreases Expression	[7]
SUZ domain-containing protein 1 (SZRD1)	OTJMEJWT	SZRD1_HUMAN	Decreases Expression	[7]
Leucine-rich repeat-containing protein 28 (LRRC28)	OTFTT6VN	LRC28_HUMAN	Increases Expression	[7]
Mitochondrial basic amino acids transporter (SLC25A29)	OT09PIFE	S2529_HUMAN	Increases Expression	[7]
Equilibrative nucleobase transporter 1 (SLC43A3)	OTR60ZLA	S43A3_HUMAN	Decreases Expression	[7]
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	OTI0DU9Y	PCSK9_HUMAN	Increases Expression	[7]
E3 ubiquitin-protein ligase RNF149 (RNF149)	OT6SBKQV	RN149_HUMAN	Increases Expression	[7]
F-box only protein 25 (FBXO25)	OTDFA7F4	FBX25_HUMAN	Increases Expression	[7]
Solute carrier family 2, facilitated glucose transporter member 14 (SLC2A14)	OTBFIOVY	GTR14_HUMAN	Increases Expression	[7]
Membrane progestin receptor beta (PAQR8)	OTGZ8W9F	PAQR8_HUMAN	Increases Expression	[7]
Nuclear receptor subfamily 4 group A member 3 (NR4A3)	OTPBE9R1	NR4A3_HUMAN	Increases Expression	[7]
La-related protein 4B (LARP4B)	OT2HI0QE	LAR4B_HUMAN	Increases Expression	[7]
Collagen triple helix repeat-containing protein 1 (CTHRC1)	OTV88X2G	CTHR1_HUMAN	Increases Expression	[7]
BTB/POZ domain-containing protein KCTD12 (KCTD12)	OTPYKT4Z	KCD12_HUMAN	Decreases Expression	[7]
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 (MAGI1)	OTMV4ASV	MAGI1_HUMAN	Increases Expression	[7]
Sialidase-1 (NEU1)	OTH9BY8Y	NEUR1_HUMAN	Increases Expression	[7]
Galactosylceramide sulfotransferase (GAL3ST1)	OTSFFZRD	G3ST1_HUMAN	Decreases Expression	[7]
Junctional adhesion molecule C (JAM3)	OTX0F9QL	JAM3_HUMAN	Decreases Expression	[7]
SLIT and NTRK-like protein 2 (SLITRK2)	OTPVI22J	SLIK2_HUMAN	Increases Expression	[7]
Anaphase-promoting complex subunit 1 (ANAPC1)	OT2YY35L	APC1_HUMAN	Increases Expression	[7]
Anthrax toxin receptor 1 (ANTXR1)	OT5W1GPC	ANTR1_HUMAN	Affects Expression	[7]
Ras-related GTP-binding protein D (RRAGD)	OTXLVWAH	RRAGD_HUMAN	Increases Expression	[7]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Affects Expression	[7]
Intersectin-2 (ITSN2)	OT8S0OO8	ITSN2_HUMAN	Increases Expression	[7]
Probable ribosome biogenesis protein RLP24 (RSL24D1)	OT6KI56F	RLP24_HUMAN	Increases Expression	[7]
Transcription elongation factor A protein-like 9 (TCEAL9)	OT4UHDB5	TCAL9_HUMAN	Increases Expression	[7]
Histone deacetylase 9 (HDAC9)	OTO8O0LF	HDAC9_HUMAN	Increases Expression	[7]
Phosphoserine aminotransferase (PSAT1)	OTVV1YV9	SERC_HUMAN	Increases Expression	[7]
Chloride intracellular channel protein 4 (CLIC4)	OT6KTPKD	CLIC4_HUMAN	Increases Expression	[7]
Alpha-2-macroglobulin (A2M)	OTFTX90K	A2MG_HUMAN	Increases Expression	[8]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Expression	[8]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Increases Expression	[8]
Lymphotoxin-alpha (LTA)	OTUC3S76	TNFB_HUMAN	Increases Expression	[8]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases Expression	[8]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Decreases Expression	[8]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Decreases Expression	[8]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Decreases Expression	[8]
Serum amyloid P-component (APCS)	OT76JZ8Z	SAMP_HUMAN	Decreases Expression	[8]
Beta-2-glycoprotein 1 (APOH)	OTFMUX6O	APOH_HUMAN	Increases Expression	[8]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Decreases Expression	[8]
Granulocyte-macrophage colony-stimulating factor (CSF2)	OT1M7D28	CSF2_HUMAN	Decreases Expression	[8]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Decreases Expression	[8]
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Increases Expression	[8]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Decreases Expression	[8]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[8]
Stromelysin-1 (MMP3)	OTGBI74Z	MMP3_HUMAN	Decreases Expression	[8]
Coagulation factor VII (F7)	OTGNJ97M	FA7_HUMAN	Decreases Expression	[8]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Increases Expression	[8]
Granulocyte colony-stimulating factor (CSF3)	OT9GC6TP	CSF3_HUMAN	Decreases Expression	[8]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[8]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Increases Expression	[8]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[8]
Prostatic acid phosphatase (ACP3)	OTSIM0YG	PPAP_HUMAN	Decreases Expression	[8]
Kit ligand (KITLG)	OTB9AVQ4	SCF_HUMAN	Decreases Expression	[8]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Decreases Expression	[8]
Brain-derived neurotrophic factor (BDNF)	OTLGH7EW	BDNF_HUMAN	Decreases Expression	[8]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Expression	[8]
Interleukin-13 (IL13)	OTI4YS3Y	IL13_HUMAN	Increases Expression	[8]
Thrombopoietin (THPO)	OTO73DZ2	TPO_HUMAN	Increases Expression	[8]
Interleukin-15 (IL15)	OTQSYWQS	IL15_HUMAN	Decreases Expression	[8]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Decreases Expression	[8]
Pappalysin-1 (PAPPA)	OTTTG9PG	PAPP1_HUMAN	Decreases Expression	[8]
Pro-interleukin-16 (IL16)	OTZ2MO6B	IL16_HUMAN	Increases Expression	[8]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Increases Expression	[8]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Decreases Expression	[25]
Neurogenic locus notch homolog protein 1 (NOTCH1)	OTI1WADQ	NOTC1_HUMAN	Increases Expression	[25]
Proto-oncogene c-Rel (REL)	OTTCKMAC	REL_HUMAN	Decreases Expression	[25]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Activity	[26]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[27]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Decreases Expression	[28]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Decreases Expression	[29]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[30]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Decreases Expression	[23]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[31]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[32]
Zinc finger protein GLI2 (GLI2)	OTIRV97L	GLI2_HUMAN	Affects Expression	[23]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Increases Expression	[33]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Decreases Expression	[23]
Serine/threonine-protein kinase B-raf (BRAF)	OT7S81XQ	BRAF_HUMAN	Decreases Expression	[23]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[31]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Affects Expression	[21]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[34]
Insulin-like growth factor-binding protein 3 (IGFBP3)	OTIX63TX	IBP3_HUMAN	Affects Expression	[23]
Cannabinoid receptor 1 (CNR1)	OTEALO6G	CNR1_HUMAN	Increases Expression	[35]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[36]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[24]
Aryl hydrocarbon receptor nuclear translocator (ARNT)	OTMSIEZY	ARNT_HUMAN	Increases Expression	[23]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[24]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Increases Methylation	[37]
Cannabinoid receptor 2 (CNR2)	OTYP9P43	CNR2_HUMAN	Increases Expression	[35]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Increases Expression	[38]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Increases Expression	[23]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Activity	[39]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[40]
Proliferation marker protein Ki-67 (MKI67)	OTA8N1QI	KI67_HUMAN	Decreases Expression	[27]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3)	OTI2OREX	MP2K3_HUMAN	Increases Phosphorylation	[41]
Transcription factor SOX-2 (SOX2)	OTFAWCAU	SOX2_HUMAN	Increases Expression	[38]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[42]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6)	OTK13JKC	MP2K6_HUMAN	Increases Phosphorylation	[41]
Serine/threonine-protein kinase PLK1 (PLK1)	OTRZX45T	PLK1_HUMAN	Decreases Expression	[23]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[40]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Cleavage	[43]
C-X-C chemokine receptor type 4 (CXCR4)	OTUFSBX2	CXCR4_HUMAN	Affects Expression	[23]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Decreases Expression	[23]
POU domain, class 5, transcription factor 1 (POU5F1)	OTDHHN7O	PO5F1_HUMAN	Decreases Expression	[21]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Increases Expression	[44]
Regenerating islet-derived protein 3-alpha (REG3A)	OT0BVQRB	REG3A_HUMAN	Decreases Expression	[42]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[24]
Protein patched homolog 1 (PTCH1)	OTMG07H5	PTC1_HUMAN	Affects Expression	[23]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[40]
Sonic hedgehog protein (SHH)	OTOG2BXF	SHH_HUMAN	Decreases Expression	[23]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Expression	[31]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1)	OT2363Z9	T53I1_HUMAN	Increases Expression	[42]
Protein smoothened (SMO)	OTXXE208	SMO_HUMAN	Increases Expression	[38]
Homeobox protein NANOG (NANOG)	OTUEY1FM	NANOG_HUMAN	Decreases Expression	[38]
Axin-2 (AXIN2)	OTRMGQNU	AXIN2_HUMAN	Affects Expression	[23]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D)	OT1RWFV0	PDE4D_HUMAN	Increases ADR	[45]
Focal adhesion kinase 1 (PTK2)	OT3Q1JDY	FAK1_HUMAN	Decreases Response To Substance	[46]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Affects Response To Substance	[47]
Splicing factor 45 (RBM17)	OT9ROJCL	SPF45_HUMAN	Decreases Response To Substance	[48]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Affects Response To Substance	[49]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Decreases Response To Substance	[50]
Oxysterol-binding protein 2 (OSBP2)	OTDGLB4J	OSBP2_HUMAN	Increases ADR	[45]
Proto-oncogene tyrosine-protein kinase Src (SRC)	OTETYX40	SRC_HUMAN	Decreases Response To Substance	[51]
Equilibrative nucleoside transporter 3 (SLC29A3)	OTGLX8XU	S29A3_HUMAN	Affects Transport	[52]
Probable ATP-dependent RNA helicase DDX53 (DDX53)	OTHK3EGZ	DDX53_HUMAN	Affects Response To Substance	[53]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Decreases Response To Substance	[54]
Pyruvate kinase PKM (PKM)	OTLHHMC2	KPYM_HUMAN	Affects Response To Substance	[27]
Equilibrative nucleoside transporter 1 (SLC29A1)	OTLOOZZS	S29A1_HUMAN	Increases Response To Substance	[55]
Alpha-protein kinase 3 (ALPK3)	OTLUYSMO	ALPK3_HUMAN	Increases ADR	[45]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Response To Substance	[56]
Death-associated protein kinase 1 (DAPK1)	OTNCNUCO	DAPK1_HUMAN	Increases ADR	[57]
Cytochrome c oxidase subunit 3 (COX3)	OTNNGBYJ	COX3_HUMAN	Decreases Response To Substance	[58]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Decreases Response To Substance	[59]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Increases ADR	[60]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Affects Response To Substance	[61]
3-phosphoinositide-dependent protein kinase 1 (PDPK1)	OTT09ZVP	PDPK1_HUMAN	Decreases Response To Substance	[62]
Nucleophosmin (NPM1)	OTTBYYT0	NPM_HUMAN	Decreases Response To Substance	[63]
Serine/threonine-protein kinase SMG1 (SMG1)	OTTS3SXE	SMG1_HUMAN	Decreases Response To Substance	[64]
ATP-dependent DNA helicase PIF1 (PIF1)	OTUHKKVP	PIF1_HUMAN	Decreases Response To Substance	[34]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Response To Substance	[65]
Ribonucleoside-diphosphate reductase large subunit (RRM1)	OTXGQOR9	RIR1_HUMAN	Increases ADR	[66]
Olfactory receptor 4D6 (OR4D6)	OTXJKUT1	OR4D6_HUMAN	Affects Response To Substance	[53]
PDZ domain-containing protein GIPC1 (GIPC1)	OTXLVCPJ	GIPC1_HUMAN	Affects Response To Substance	[67]
Integrin-linked protein kinase (ILK)	OTYG2FD1	ILK_HUMAN	Affects Response To Substance	[47]
Poly polymerase 2 (PARP2)	OTYL81ZI	PARP2_HUMAN	Decreases Response To Substance	[68]

Indication(s) of Paclitaxel

Disease Entry	ICD 11	Status	REF
Breast carcinoma	N.A.	Approved	[6]
Cutaneous melanoma	2C30	Approved	[6]
Cutaneous squamous cell carcinoma	2C30	Approved	[6]
Epithelial ovarian cancer	2B5D	Approved	[6]
Extragonadal germ cell tumor	N.A.	Approved	[6]
Fallopian tube neoplasm	N.A.	Approved	[6]
Gastroesophageal junction adenocarcinoma	2B71	Approved	[6]
Inflammatory breast cancer	2C62	Approved	[6]
Kaposi sarcoma	2B57	Approved	[6]
Lung adenocarcinoma	N.A.	Approved	[6]
Lung cancer	2C25.0	Approved	[6]
Non-small-cell lung cancer	2C25.Y	Approved	[6]
Ocular hypertension	9C61.01	Approved	[6]
Ovarian neoplasm	N.A.	Approved	[6]
Ovarian serous cystadenocarcinoma	N.A.	Approved	[6]
Pain	MG30-MG3Z	Approved	[6]
Pancreatic ductal carcinoma	2C10.0	Approved	[6]
Primary peritoneal carcinoma	N.A.	Approved	[6]
Testicular germ cell tumor	N.A.	Approved	[6]
Urethral cancer	2C93	Approved	[6]
Lung large cell carcinoma	N.A.	Investigative	[6]

Paclitaxel Interacts with 11 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[81]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[82]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[83]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[84]
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[85]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[86]
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[87]
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[88]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[89]
TAP-like protein (ABCB9)	DT68UV2	ABCB9_HUMAN	Substrate	[90]
Multidrug resistance-associated protein 7 (ABCC10)	DTPS120	MRP7_HUMAN	Substrate	[91]

Paclitaxel Interacts with 478 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Decreases Expression	[92]
ATP-binding cassette sub-family C member 10 (ABCC10)	OT2JRWWJ	MRP7_HUMAN	Increases Expression	[93]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Expression	[93]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Decreases Response To Substance	[94]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[95]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Response To Substance	[96]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Decreases Response To Substance	[97]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Increases Transport	[85]
Cyclin-dependent kinase 20 (CDK20)	OTOLNN68	CDK20_HUMAN	Decreases Expression	[98]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Increases ADR	[60]
Lipoprotein lipase (LPL)	OTTW0267	LIPL_HUMAN	Increases ADR	[60]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[99]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[100]
TNF receptor-associated factor 1 (TRAF1)	OTTLM5RU	TRAF1_HUMAN	Decreases Expression	[98]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Decreases Expression	[101]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[101]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[73]
Poly polymerase 1 (PARP1)	OTIESHK4	PARP1_ARATH	Increases ADR	[60]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[102]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Increases Activity	[103]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[104]
Dihydropyrimidine dehydrogenase (DPYD)	OTWRF2NR	DPYD_HUMAN	Decreases Expression	[69]
Arylamine N-acetyltransferase 1 (NAT1)	OTCCNQ3H	ARY1_HUMAN	Decreases Activity	[105]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	OTAYZMOY	SIR1_HUMAN	Decreases Expression	[106]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Decreases Expression	[99]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Increases Expression	[99]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Decreases Activity	[107]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Decreases Activity	[107]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Decreases Activity	[107]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[108]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[109]
DNA fragmentation factor subunit alpha (DFFA)	OTFPFMT8	DFFA_HUMAN	Decreases Expression	[71]
Sulfhydryl oxidase 1 (QSOX1)	OT4ZPK4P	QSOX1_HUMAN	Decreases Expression	[70]
Serine/threonine-protein kinase PLK4 (PLK4)	OTV8KZDZ	PLK4_HUMAN	Decreases Expression	[70]
TNF receptor-associated factor 5 (TRAF5)	OTSBTLO0	TRAF5_HUMAN	Decreases Expression	[70]
Myc box-dependent-interacting protein 1 (BIN1)	OTK8O0X8	BIN1_HUMAN	Increases Expression	[110]
Nucleoside diphosphate kinase, mitochondrial (NME4)	OT2JTT42	NDKM_HUMAN	Decreases Expression	[71]
Potassium channel subfamily K member 3 (KCNK3)	OTWMAV6G	KCNK3_HUMAN	Increases Expression	[71]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Increases Expression	[101]
Acyl-coenzyme A thioesterase 8 (ACOT8)	OTHY684G	ACOT8_HUMAN	Decreases Expression	[111]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Expression	[112]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[109]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Increases Expression	[110]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Increases Expression	[113]
Mitogen-activated protein kinase 13 (MAPK13)	OT0W9GE7	MK13_HUMAN	Increases Expression	[71]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[114]
High affinity copper uptake protein 1 (SLC31A1)	OTXLRTUB	COPT1_HUMAN	Increases Expression	[93]
ATP-binding cassette sub-family C member 5 (ABCC5)	OT34G4US	MRP5_HUMAN	Increases Expression	[93]
N-glycosylase/DNA lyase (OGG1)	OTJ97TF3	OGG1_HUMAN	Increases Expression	[71]
Retinoschisin (RS1)	OTEW1ZM5	XLRS1_HUMAN	Decreases Secretion	[115]
Kunitz-type protease inhibitor 2 (SPINT2)	OTQV7BKQ	SPIT2_HUMAN	Decreases Expression	[110]
Adenylate cyclase type 6 (ADCY6)	OTFOY4WW	ADCY6_HUMAN	Decreases Expression	[70]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Increases Expression	[113]
Mitotic checkpoint protein BUB3 (BUB3)	OTU91HAU	BUB3_HUMAN	Increases Expression	[71]
Phospholipid phosphatase 2 (PLPP2)	OT0BQAXX	PLPP2_HUMAN	Decreases Expression	[110]
Myelin protein zero-like protein 2 (MPZL2)	OTKFNDUI	MPZL2_HUMAN	Decreases Expression	[110]
Dual specificity protein phosphatase CDC14B (CDC14B)	OTAESVOZ	CC14B_HUMAN	Decreases Expression	[98]
Hyaluronan mediated motility receptor (HMMR)	OT4M0JTZ	HMMR_HUMAN	Decreases Expression	[71]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1)	OTY9R6FZ	ERN1_HUMAN	Increases Expression	[116]
Death effector domain-containing protein (DEDD)	OTIL349E	DEDD_HUMAN	Decreases Expression	[70]
Serine hydrolase RBBP9 (RBBP9)	OT0Z04L6	RBBP9_HUMAN	Decreases Expression	[70]
Tumor necrosis factor ligand superfamily member 13 (TNFSF13)	OT90OWIO	TNF13_HUMAN	Increases Expression	[98]
ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial (CLPX)	OTIT4JL0	CLPX_HUMAN	Increases Expression	[71]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Increases Expression	[98]
Securin (PTTG1)	OTIMYS4W	PTTG1_HUMAN	Affects Expression	[117]
G1/S-specific cyclin-E2 (CCNE2)	OTBBUKQQ	CCNE2_HUMAN	Decreases Expression	[70]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Decreases Expression	[118]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Expression	[98]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[71]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Expression	[98]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Expression	[119]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Increases Expression	[110]
Collagen alpha-1(IV) chain (COL4A1)	OTL6D1YE	CO4A1_HUMAN	Increases Expression	[110]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Increases Expression	[120]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Increases Phosphorylation	[121]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[122]
Thy-1 membrane glycoprotein (THY1)	OTVONVTB	THY1_HUMAN	Increases Expression	[110]
Apolipoprotein D (APOD)	OTT77XW8	APOD_HUMAN	Increases Expression	[110]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA)	OTWJTCRK	PCCA_HUMAN	Decreases Expression	[71]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Phosphorylation	[116]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[123]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[124]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Phosphorylation	[125]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Expression	[126]
Keratin, type I cytoskeletal 18 (KRT18)	OTVLQFIP	K1C18_HUMAN	Increases Expression	[127]
Gelsolin (GSN)	OT4KS2UU	GELS_HUMAN	Decreases Expression	[70]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Increases Phosphorylation	[128]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Expression	[98]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Decreases Expression	[111]
Prosaposin (PSAP)	OTUOEKY7	SAP_HUMAN	Decreases Expression	[70]
Collagen alpha-2(IV) chain (COL4A2)	OTJK1LKN	CO4A2_HUMAN	Increases Expression	[110]
SPARC (SPARC)	OTPN90H0	SPRC_HUMAN	Increases Expression	[110]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[129]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[123]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Localization	[130]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Decreases Expression	[131]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[132]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[132]
Collagen alpha-1(VI) chain (COL6A1)	OTYKSCOB	CO6A1_HUMAN	Increases Expression	[110]
Collagen alpha-2(VI) chain (COL6A2)	OTQC6PPO	CO6A2_HUMAN	Increases Expression	[110]
ADP/ATP translocase 1 (SLC25A4)	OTKYLK2J	ADT1_HUMAN	Decreases Expression	[70]
Bone morphogenetic protein 4 (BMP4)	OTPZMDFH	BMP4_HUMAN	Decreases Expression	[74]
Elongation factor 2 (EEF2)	OTZ7SZ39	EF2_HUMAN	Decreases Expression	[70]
Glial fibrillary acidic protein (GFAP)	OTQ01ZAS	GFAP_HUMAN	Increases Expression	[133]
Interleukin-1 receptor type 1 (IL1R1)	OTTU8959	IL1R1_HUMAN	Decreases Expression	[71]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Increases Expression	[54]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[134]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Decreases Expression	[110]
Integrin beta-6 (ITGB6)	OTI3DJ7U	ITB6_HUMAN	Decreases Expression	[110]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[116]
DNA ligase 1 (LIG1)	OTEEQS43	DNLI1_HUMAN	Decreases Expression	[70]
Sodium/hydrogen exchanger 1 (SLC9A1)	OT6HNHFV	SL9A1_HUMAN	Decreases Activity	[135]
Integrin alpha-L (ITGAL)	OTCUQAIS	ITAL_HUMAN	Decreases Expression	[124]
Ephrin-A1 (EFNA1)	OTU2NUA2	EFNA1_HUMAN	Decreases Expression	[110]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3)	OTVLI4DD	TNAP3_HUMAN	Increases Expression	[98]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Expression	[123]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)	OTBZKX4P	ROA2_HUMAN	Decreases Expression	[70]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[110]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[111]
Follicle-stimulating hormone receptor (FSHR)	OT9MVMLI	FSHR_HUMAN	Decreases Expression	[74]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[132]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Increases Activity	[136]
Signal transducer CD24 (CD24)	OT7CODJ4	CD24_HUMAN	Decreases Expression	[110]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Decreases Expression	[137]
Protein S100-P (S100P)	OTJCXNJG	S100P_HUMAN	Decreases Expression	[110]
Protein S100-A4 (S100A4)	OTLRGFSQ	S10A4_HUMAN	Increases Expression	[110]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[74]
Long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADL)	OTP7Y0UF	ACADL_HUMAN	Decreases Expression	[71]
Caspase-1 (CASP1)	OTZ3YQFU	CASP1_HUMAN	Increases Expression	[119]
M-phase inducer phosphatase 3 (CDC25C)	OTPQI71S	MPIP3_HUMAN	Decreases Expression	[98]
Adenylosuccinate synthetase isozyme 2 (ADSS2)	OTW26XXB	PURA2_HUMAN	Decreases Expression	[71]
RAC-beta serine/threonine-protein kinase (AKT2)	OTBB632K	AKT2_HUMAN	Increases Phosphorylation	[138]
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1)	OTFRWOLM	HNRH1_HUMAN	Decreases Expression	[70]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Increases Expression	[71]
Syndecan-2 (SDC2)	OTEEHY1D	SDC2_HUMAN	Increases Expression	[110]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Decreases Phosphorylation	[74]
Tyrosine-protein phosphatase non-receptor type 7 (PTPN7)	OTXYSIIV	PTN7_HUMAN	Increases Expression	[71]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[71]
Fibrillin-1 (FBN1)	OTYCJT63	FBN1_HUMAN	Increases Expression	[110]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[116]
Pigment epithelium-derived factor (SERPINF1)	OTWZH98J	PEDF_HUMAN	Increases Expression	[110]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Decreases Expression	[139]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[140]
Collagen alpha-1(XVIII) chain (COL18A1)	OTJFUH6O	COIA1_HUMAN	Increases Expression	[110]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Activity	[141]
Replication factor C subunit 5 (RFC5)	OTAD79RT	RFC5_HUMAN	Decreases Expression	[71]
Serine/threonine-protein kinase mTOR (MTOR)	OTHH8KU7	MTOR_HUMAN	Decreases Phosphorylation	[132]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[142]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases Activity	[143]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Increases Expression	[144]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[145]
Isocitrate dehydrogenase , mitochondrial (IDH2)	OTTQA4PB	IDHP_HUMAN	Decreases Expression	[70]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1)	OTNWHUJ1	AL9A1_HUMAN	Increases Expression	[71]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Decreases Expression	[111]
Centromere protein F (CENPF)	OT7AG0SW	CENPF_HUMAN	Increases Expression	[146]
Caspase-4 (CASP4)	OTVQTV1L	CASP4_HUMAN	Increases Expression	[98]
NADH dehydrogenase flavoprotein 1, mitochondrial (NDUFV1)	OTEVK4WW	NDUV1_HUMAN	Decreases Expression	[70]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[147]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Decreases Expression	[111]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Expression	[71]
Cyclin-dependent kinase 7 (CDK7)	OTAO19PQ	CDK7_HUMAN	Increases Activity	[148]
Palmitoyl-protein thioesterase 1 (PPT1)	OTM3S4DE	PPT1_HUMAN	Decreases Expression	[111]
Dual specificity protein phosphatase 3 (DUSP3)	OTPJX9B4	DUS3_HUMAN	Decreases Expression	[70]
Matrix metalloproteinase-16 (MMP16)	OTSFQ2BJ	MMP16_HUMAN	Decreases Expression	[98]
Caspase-5 (CASP5)	OT0F2THD	CASP5_HUMAN	Increases Expression	[98]
Cyclin-H (CCNH)	OTKDU3SR	CCNH_HUMAN	Increases Expression	[71]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1)	OTK71JYU	TCP4_HUMAN	Decreases Expression	[71]
Epithelial membrane protein 3 (EMP3)	OTODMJ1D	EMP3_HUMAN	Increases Expression	[110]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Expression	[98]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Expression	[98]
Cadherin-11 (CDH11)	OTIZKPTF	CAD11_HUMAN	Increases Expression	[110]
Tumor protein D52 (TPD52)	OTPKSK43	TPD52_HUMAN	Decreases Expression	[110]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Cleavage	[133]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Activity	[149]
Eukaryotic initiation factor 4A-I (EIF4A1)	OTMTBX6N	IF4A1_HUMAN	Decreases Expression	[71]
Actin, aortic smooth muscle (ACTA2)	OTEDLG8E	ACTA_HUMAN	Increases Expression	[150]
Ras-related C3 botulinum toxin substrate 1 (RAC1)	OTKRO61U	RAC1_HUMAN	Decreases Expression	[70]
SH3 domain-binding protein 2 (SH3BP2)	OT90JNBS	3BP2_HUMAN	Decreases Expression	[71]
General transcription factor II-I (GTF2I)	OTUYL1TQ	GTF2I_HUMAN	Decreases Expression	[70]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Increases Expression	[71]
Cyclin-dependent kinase 6 (CDK6)	OTR95N0X	CDK6_HUMAN	Decreases Expression	[132]
Antigen peptide transporter 1 (TAP1)	OTJL27PW	TAP1_HUMAN	Increases Expression	[93]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[112]
Copper-transporting ATPase 1 (ATP7A)	OTMR3GXP	ATP7A_HUMAN	Increases Expression	[93]
Protein kinase C delta type (PRKCD)	OTSEH90E	KPCD_HUMAN	Affects Localization	[122]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[73]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[98]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[101]
Heat shock protein beta-3 (HSPB3)	OTE67YM5	HSPB3_HUMAN	Increases Expression	[71]
Lymphocyte cytosolic protein 2 (LCP2)	OT57KE22	LCP2_HUMAN	Increases Expression	[71]
FAS-associated death domain protein (FADD)	OTV7GFHH	FADD_HUMAN	Increases Expression	[98]
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1)	OTS3FVTY	M3K1_HUMAN	Increases Cleavage	[143]
MAGUK p55 subfamily member 3 (MPP3)	OTNOL0HA	MPP3_HUMAN	Increases Expression	[71]
Rho-associated protein kinase 1 (ROCK1)	OTSXYVW1	ROCK1_HUMAN	Increases Expression	[70]
Short transient receptor potential channel 3 (TRPC3)	OTNR61OD	TRPC3_HUMAN	Increases Expression	[71]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2)	OTTUU92F	ENPP2_HUMAN	Increases Expression	[110]
Protein-tyrosine kinase 6 (PTK6)	OT7NWIQ0	PTK6_HUMAN	Increases Expression	[70]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Increases Expression	[119]
Protein BTG3 (BTG3)	OT9ANHVT	BTG3_HUMAN	Increases Expression	[71]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Decreases Expression	[71]
Caprin-1 (CAPRIN1)	OTEJAMS3	CAPR1_HUMAN	Decreases Expression	[98]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Expression	[98]
Periostin (POSTN)	OTWP62UA	POSTN_HUMAN	Increases Expression	[110]
Procollagen C-endopeptidase enhancer 1 (PCOLCE)	OTJXOAN4	PCOC1_HUMAN	Increases Expression	[110]
Transcription factor E2F5 (E2F5)	OT1XWING	E2F5_HUMAN	Increases Expression	[70]
Microtubule-associated protein RP/EB family member 1 (MAPRE1)	OTCVQD60	MARE1_HUMAN	Decreases Localization	[151]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[73]
Transcriptional regulator QRICH1 (QRICH1)	OTPVAX04	QRIC1_HUMAN	Increases Phosphorylation	[152]
Parafibromin (CDC73)	OT6JASZ1	CDC73_HUMAN	Decreases Expression	[98]
Inactive caspase-12 (CASP12)	OTY2W6FG	CASPC_HUMAN	Decreases Expression	[112]
Heme A synthase COX15 (COX15)	OTUIYHIW	COX15_HUMAN	Decreases Expression	[70]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)	OTE8GBUR	RIR2B_HUMAN	Increases Expression	[153]
Cell division cycle and apoptosis regulator protein 1 (CCAR1)	OTUXLQZZ	CCAR1_HUMAN	Increases Expression	[98]
NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	OT5Q6SVK	SIR2_HUMAN	Decreases Expression	[116]
Abnormal spindle-like microcephaly-associated protein (ASPM)	OTKXQMNA	ASPM_HUMAN	Increases Expression	[113]
Phospholipid-transporting ATPase ABCA7 (ABCA7)	OT51S50X	ABCA7_HUMAN	Increases Expression	[93]
Centromere protein S (CENPS)	OTZ4J391	CENPS_HUMAN	Increases Expression	[98]
NAD-dependent protein deacylase sirtuin-6 (SIRT6)	OTF755ZO	SIR6_HUMAN	Decreases Expression	[116]
Cholesterol transporter ABCA5 (ABCA5)	OT4B9D92	ABCA5_HUMAN	Increases Expression	[93]
MAP kinase-activating death domain protein (MADD)	OTUFYVGG	MADD_HUMAN	Decreases Expression	[70]
Mucin-16 (MUC16)	OTHPPE67	MUC16_HUMAN	Decreases Expression	[154]
Rap guanine nucleotide exchange factor 5 (RAPGEF5)	OT53VS75	RPGF5_HUMAN	Increases Expression	[71]
Estrogen receptor beta (ESR2)	OTXNR2WQ	ESR2_HUMAN	Decreases Expression	[74]
Transcription factor AP-2 gamma (TFAP2C)	OTUDIW05	AP2C_HUMAN	Decreases Expression	[110]
Caspase-10 (CASP10)	OTE6J88E	CASPA_HUMAN	Increases Expression	[98]
Engulfment and cell motility protein 3 (ELMO3)	OTQHO9VM	ELMO3_HUMAN	Increases Expression	[71]
p53 apoptosis effector related to PMP-22 (PERP)	OTP0YL53	PERP_HUMAN	Increases Expression	[98]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[155]
Cell division cycle 5-like protein (CDC5L)	OTTPFUU5	CDC5L_HUMAN	Decreases Expression	[98]
M-phase phosphoprotein 6 (MPHOSPH6)	OT6E2S48	MPH6_HUMAN	Decreases Expression	[71]
Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB)	OTUKPFOK	ROAA_HUMAN	Decreases Expression	[70]
Transmembrane protein 243 (TMEM243)	OT8NQ79G	TM243_HUMAN	Increases Expression	[156]
Cell division cycle-associated protein 7 (CDCA7)	OT12HDZY	CDCA7_HUMAN	Decreases Expression	[98]
Transmembrane gamma-carboxyglutamic acid protein 4 (PRRG4)	OT2SZQI7	TMG4_HUMAN	Decreases Expression	[110]
TRIO and F-actin-binding protein (TRIOBP)	OTGB5WHC	TARA_HUMAN	Increases Expression	[71]
ATP-binding cassette sub-family B member 6 (ABCB6)	OTPGZFES	ABCB6_HUMAN	Decreases Expression	[93]
Bridging integrator 3 (BIN3)	OTMIWWDW	BIN3_HUMAN	Decreases Expression	[71]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Increases Expression	[112]
NAD-dependent protein deacetylase sirtuin-7 (SIRT7)	OT5M4OT4	SIR7_HUMAN	Decreases Expression	[116]
Olfactomedin-like protein 3 (OLFML3)	OTDN45FN	OLFL3_HUMAN	Increases Expression	[110]
G2 and S phase-expressed protein 1 (GTSE1)	OTPP742Z	GTSE1_HUMAN	Increases Expression	[71]
ETS homologous factor (EHF)	OTY6TPWD	EHF_HUMAN	Decreases Expression	[110]
Programmed cell death 1 ligand 1 (CD274)	OTJ0VFDL	PD1L1_HUMAN	Increases Expression	[157]
DNA polymerase kappa (POLK)	OTKZ38JH	POLK_HUMAN	Decreases Expression	[70]
Protein Hook homolog 1 (HOOK1)	OTTTKV7V	HOOK1_HUMAN	Decreases Expression	[110]
PR domain zinc finger protein 4 (PRDM4)	OTD9PAZJ	PRDM4_HUMAN	Decreases Expression	[71]
F-box only protein 5 (FBXO5)	OTTR957W	FBX5_HUMAN	Affects Expression	[117]
Neurabin-1 (PPP1R9A)	OTJL2TOC	NEB1_HUMAN	Decreases Expression	[70]
Matrix metalloproteinase-17 (MMP17)	OT5TMIQ6	MMP17_HUMAN	Decreases Expression	[98]
Microtubule-associated protein RP/EB family member 3 (MAPRE3)	OTSCLETV	MARE3_HUMAN	Affects Localization	[151]
Cyclin-D-binding Myb-like transcription factor 1 (DMTF1)	OTDKO9OO	DMTF1_HUMAN	Decreases Expression	[70]
RuvB-like 2 (RUVBL2)	OTGWJ4T4	RUVB2_HUMAN	Decreases Expression	[71]
C-type lectin domain family 11 member A (CLEC11A)	OT9KBH7C	CLC11_HUMAN	Increases Expression	[110]
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B)	OTND26XR	TN13B_HUMAN	Increases Expression	[98]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5)	OT03QCLM	ATF5_HUMAN	Decreases Expression	[70]
Protein-arginine deiminase type-2 (PADI2)	OTT40K94	PADI2_HUMAN	Decreases Expression	[71]
Mitochondrial import inner membrane translocase subunit Tim22 (TIMM22)	OTJMHX1V	TIM22_HUMAN	Increases Expression	[71]
Small ribosomal subunit protein mS40 (MRPS18B)	OT1K9PFX	RT18B_HUMAN	Decreases Expression	[71]
Transforming acidic coiled-coil-containing protein 3 (TACC3)	OTRNEZTA	TACC3_HUMAN	Decreases Expression	[71]
Sorting nexin-10 (SNX10)	OT05B7BT	SNX10_HUMAN	Affects Response To Substance	[76]
Superoxide dismutase (SOD2)	OT08HOR5	Q4ZJI1_HUMAN	Increases ADR	[60]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)	OT0DZGY4	E2AK3_HUMAN	Affects Response To Substance	[76]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Decreases Response To Substance	[158]
Phospholipid phosphatase 1 (PLPP1)	OT0IIMI5	PLPP1_HUMAN	Decreases Response To Substance	[159]
Interleukin-17 receptor B (IL17RB)	OT0KDNSF	I17RB_HUMAN	Decreases Response To Substance	[159]
Oxysterol-binding protein-related protein 10 (OSBPL10)	OT0TFMBE	OSB10_HUMAN	Affects Response To Substance	[76]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13)	OT0UOKIT	NDUAD_HUMAN	Affects Response To Substance	[76]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[76]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Response To Substance	[160]
Condensin complex subunit 3 (NCAPG)	OT1AI9EO	CND3_HUMAN	Affects Response To Substance	[76]
Integrin beta-5 (ITGB5)	OT21MF51	ITB5_HUMAN	Decreases Response To Substance	[96]
NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7)	OT2CHQQ1	NDUB7_HUMAN	Affects Response To Substance	[76]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Affects Response To Substance	[76]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25)	OT2MR6O2	SNR25_HUMAN	Affects Response To Substance	[76]
Epidermal growth factor-like protein 6 (EGFL6)	OT331X59	EGFL6_HUMAN	Decreases Response To Substance	[79]
Biglycan (BGN)	OT3AV6IF	PGS1_HUMAN	Affects Response To Substance	[76]
Cytidine deaminase (CDA)	OT3HXP6N	CDD_HUMAN	Affects Response To Substance	[11]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Increases Response To Substance	[159]
Solute carrier family 12 member 2 (SLC12A2)	OT3ZJ3LH	S12A2_HUMAN	Decreases Response To Substance	[159]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2)	OT4717TF	NDUB2_HUMAN	Affects Response To Substance	[76]
High mobility group protein B1 (HMGB1)	OT4B7CPF	HMGB1_HUMAN	Affects Response To Substance	[76]
Deoxycytidylate deaminase (DCTD)	OT4FLFT4	DCTD_HUMAN	Affects Response To Substance	[76]
Sorcin (SRI)	OT4R3EAC	SORCN_HUMAN	Decreases Response To Substance	[161]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Affects Response To Substance	[119]
Ubiquitin-like protein ISG15 (ISG15)	OT53QQ7N	ISG15_HUMAN	Affects Response To Substance	[76]
MARVEL domain-containing protein 1 (MARVELD1)	OT5CPOJE	MALD1_HUMAN	Increases Response To Substance	[162]
Small ribosomal subunit protein uS15m (MRPS15)	OT5HRAPP	RT15_HUMAN	Affects Response To Substance	[76]
RAC-gamma serine/threonine-protein kinase (AKT3)	OT5M2LFI	AKT3_HUMAN	Affects Response To Substance	[138]
Signal recognition particle receptor subunit alpha (SRPRA)	OT5NMYTY	SRPRA_HUMAN	Affects Response To Substance	[76]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Increases Response To Substance	[159]
Beta-sarcoglycan (SGCB)	OT5R5LAT	SGCB_HUMAN	Affects Response To Substance	[76]
Collagen alpha-2(V) chain (COL5A2)	OT5VOSQE	CO5A2_HUMAN	Decreases Response To Substance	[79]
Transmembrane protein 135 (TMEM135)	OT63ZT3X	TM135_HUMAN	Affects Response To Substance	[76]
Farnesyl pyrophosphate synthase (FDPS)	OT6CKWV5	FPPS_HUMAN	Increases Response To Substance	[96]
Ferritin heavy chain (FTH1)	OT6IFS0O	FRIH_HUMAN	Decreases Response To Substance	[96]
DNA topoisomerase 2-alpha (TOP2A)	OT6LPS08	TOP2A_HUMAN	Increases Response To Substance	[96]
Claudin-3 (CLDN3)	OT71MN9S	CLD3_HUMAN	Decreases Response To Substance	[159]
Plasminogen activator inhibitor 2 (SERPINB2)	OT72QLZB	PAI2_HUMAN	Affects Response To Substance	[76]
DNA-binding protein RFX5 (RFX5)	OT73KJ5P	RFX5_HUMAN	Decreases Response To Substance	[96]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Decreases Response To Substance	[163]
Large ribosomal subunit protein P1 (RPLP1)	OT7B0SIB	RLA1_HUMAN	Decreases Response To Substance	[96]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Decreases Response To Substance	[164]
Nucleolar and spindle-associated protein 1 (NUSAP1)	OT85HIJ5	NUSAP_HUMAN	Affects Response To Substance	[76]
Peroxisomal multifunctional enzyme type 2 (HSD17B4)	OT8733D7	DHB4_HUMAN	Affects Response To Substance	[76]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Response To Substance	[62]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)	OT8KME51	BUB1B_HUMAN	Affects Response To Substance	[165]
Thrombomodulin (THBD)	OT8VHLKY	TRBM_HUMAN	Decreases Response To Substance	[166]
Transcriptional repressor CTCF (CTCF)	OT8ZB70U	CTCF_HUMAN	Decreases Response To Substance	[96]
Neuron navigator 3 (NAV3)	OT97M1TR	NAV3_HUMAN	Affects Response To Substance	[76]
Solute carrier family 22 member 18 (SLC22A18)	OT9C3KR4	S22AI_HUMAN	Decreases Response To Substance	[159]
Gamma-interferon-inducible lysosomal thiol reductase (IFI30)	OT9DERT1	GILT_HUMAN	Decreases Response To Substance	[96]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Response To Substance	[96]
Beta-glucuronidase (GUSB)	OT9N1DK3	BGLR_HUMAN	Affects Response To Substance	[76]
FXYD domain-containing ion transport regulator 3 (FXYD3)	OT9PPRHE	FXYD3_HUMAN	Increases Response To Substance	[96]
Proteasome subunit beta type-6 (PSMB6)	OT9VXPNW	PSB6_HUMAN	Affects Response To Substance	[76]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3)	OTA2TBWS	HMGN3_HUMAN	Affects Response To Substance	[76]
Atypical chemokine receptor 3 (ACKR3)	OTA6GA4F	ACKR3_HUMAN	Decreases Response To Substance	[96]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4)	OTA6ICI2	NUD4B_HUMAN	Affects Response To Substance	[76]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Response To Substance	[167]
Proteasome subunit alpha type-4 (PSMA4)	OTAD2XXI	PSA4_HUMAN	Affects Response To Substance	[76]
POM121 and ZP3 fusion protein (POMZP3)	OTAH2JOK	POZP3_HUMAN	Affects Response To Substance	[76]
Mediator of RNA polymerase II transcription subunit 4 (MED4)	OTALFN4S	MED4_HUMAN	Affects Response To Substance	[76]
snRNA-activating protein complex subunit 1 (SNAPC1)	OTAPN1NI	SNPC1_HUMAN	Increases Response To Substance	[159]
Collagen alpha-3(VI) chain (COL6A3)	OTAS6R6I	CO6A3_HUMAN	Affects Response To Substance	[76]
MAP kinase-activated protein kinase 5 (MAPKAPK5)	OTAZHPVK	MAPK5_HUMAN	Affects Response To Substance	[76]
Desmoplakin (DSP)	OTB2MOP8	DESP_HUMAN	Affects Response To Substance	[76]
Large ribosomal subunit protein mL40 (MRPL40)	OTB2QZDY	RM40_HUMAN	Affects Response To Substance	[76]
Large ribosomal subunit protein uL16 (RPL10)	OTBHOZGC	RL10_HUMAN	Affects Response To Substance	[76]
Prominin-1 (PROM1)	OTBHV8NX	PROM1_HUMAN	Decreases Response To Substance	[168]
Probable ATP-dependent RNA helicase DDX23 (DDX23)	OTBJHS8C	DDX23_HUMAN	Affects Response To Substance	[76]
Coatomer subunit epsilon (COPE)	OTBKHBT7	COPE_HUMAN	Affects Response To Substance	[76]
Protein FAM3C (FAM3C)	OTBR6U9G	FAM3C_HUMAN	Affects Response To Substance	[76]
Transmembrane protein 134 (TMEM134)	OTBX9H9D	TM134_HUMAN	Affects Response To Substance	[76]
Tight junction protein ZO-3 (TJP3)	OTC1K8HC	ZO3_HUMAN	Decreases Response To Substance	[159]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Affects Response To Substance	[169]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C)	OTCLOV90	CDN2C_HUMAN	Affects Response To Substance	[76]
Cytochrome c oxidase copper chaperone (COX17)	OTCP4LH2	COX17_HUMAN	Affects Response To Substance	[76]
Trefoil factor 1 (TFF1)	OTCYQH4F	TFF1_HUMAN	Increases Response To Substance	[96]
S-phase kinase-associated protein 2 (SKP2)	OTD5B41X	SKP2_HUMAN	Affects Response To Substance	[76]
Integrin alpha-1 (ITGA1)	OTDITIST	ITA1_HUMAN	Increases Response To Substance	[79]
Stathmin (STMN1)	OTDJ4RV0	STMN1_HUMAN	Affects Response To Substance	[170]
Gamma-adducin (ADD3)	OTDRSHAZ	ADDG_HUMAN	Affects Response To Substance	[76]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Decreases Response To Substance	[96]
Superkiller complex protein 8 (SKIC8)	OTDSQYDN	SKI8_HUMAN	Affects Response To Substance	[76]
DNA-binding protein RFXANK (RFXANK)	OTDX1026	RFXK_HUMAN	Affects Response To Substance	[76]
Transcription initiation factor TFIID subunit 1 (TAF1)	OTDYS5G4	TAF1_HUMAN	Affects Response To Substance	[171]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7)	OTE0EG10	EFCB7_HUMAN	Affects Response To Substance	[76]
Glucose-6-phosphate isomerase (GPI)	OTEGSRXG	G6PI_HUMAN	Affects Response To Substance	[76]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)	OTEOT8GI	GFRP_HUMAN	Decreases Response To Substance	[159]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13)	OTESFZSO	PTN13_HUMAN	Increases Response To Substance	[159]
Rho GDP-dissociation inhibitor 1 (ARHGDIA)	OTEXWJDO	GDIR1_HUMAN	Affects Response To Substance	[172]
Caveolin-1 (CAV1)	OTEZUR1L	CAV1_HUMAN	Increases Response To Substance	[96]
Serglycin (SRGN)	OTFAVSX0	SRGN_HUMAN	Affects Response To Substance	[76]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A)	OTFBU4GD	P3C2A_HUMAN	Affects Response To Substance	[76]
Laminin subunit alpha-2 (LAMA2)	OTFROQWE	LAMA2_HUMAN	Increases Response To Substance	[79]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Affects Response To Substance	[76]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1)	OTGPN3P8	TIA1_HUMAN	Affects Response To Substance	[76]
Stanniocalcin-1 (STC1)	OTGVVXYF	STC1_HUMAN	Affects Response To Substance	[76]
Gasdermin-D (GSDMD)	OTH39BKI	GSDMD_HUMAN	Affects Response To Substance	[119]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Affects Response To Substance	[76]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Increases Response To Substance	[78]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Response To Substance	[173]
Metallothionein-2 (MT2A)	OTHOACHD	MT2_HUMAN	Increases Response To Substance	[96]
Neurogenic locus notch homolog protein 1 (NOTCH1)	OTI1WADQ	NOTC1_HUMAN	Decreases Response To Substance	[174]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Affects Response To Substance	[76]
G2/mitotic-specific cyclin-B2 (CCNB2)	OTIEXTDK	CCNB2_HUMAN	Affects Response To Substance	[76]
Polycystin-2 (PKD2)	OTIXBU8H	PKD2_HUMAN	Increases Response To Substance	[159]
G/T mismatch-specific thymine DNA glycosylase (TDG)	OTJB0YIH	TDG_HUMAN	Affects Response To Substance	[76]
E3 ubiquitin-protein ligase FANCL (FANCL)	OTJC7QPQ	FANCL_HUMAN	Affects Response To Substance	[76]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1)	OTJISZOX	PLCE1_HUMAN	Decreases Response To Substance	[159]
Transmembrane protein 168 (TMEM168)	OTJKZ6G9	TM168_HUMAN	Affects Response To Substance	[76]
Plakophilin-2 (PKP2)	OTJOVF68	PKP2_HUMAN	Decreases Response To Substance	[159]
C-X-C chemokine receptor type 6 (CXCR6)	OTK9R50G	CXCR6_HUMAN	Decreases Response To Substance	[96]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Increases Response To Substance	[159]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1)	OTKBUQXP	NDUA1_HUMAN	Affects Response To Substance	[76]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Increases Response To Substance	[159]
Serine/threonine-protein kinase PLK2 (PLK2)	OTKMJXJ8	PLK2_HUMAN	Increases ADR	[60]
Galectin-4 (LGALS4)	OTKQCG0H	LEG4_HUMAN	Decreases Response To Substance	[159]
Methylsterol monooxygenase 1 (MSMO1)	OTKV62RZ	MSMO1_HUMAN	Affects Response To Substance	[76]
Leukocyte surface antigen CD47 (CD47)	OTLDZ0KZ	CD47_HUMAN	Decreases Response To Substance	[96]
Pyruvate kinase PKM (PKM)	OTLHHMC2	KPYM_HUMAN	Affects Response To Substance	[76]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Increases Response To Substance	[160]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Increases Response To Substance	[78]
Peptidyl-prolyl cis-trans isomerase B (PPIB)	OTLPH6KN	PPIB_HUMAN	Affects Response To Substance	[76]
Annexin A8 (ANXA8)	OTLSSQCY	ANXA8_HUMAN	Increases Response To Substance	[159]
Keratin, type II cytoskeletal 7 (KRT7)	OTLT3JFN	K2C7_HUMAN	Increases Response To Substance	[159]
Lysosome-associated membrane glycoprotein 2 (LAMP2)	OTLUGEJC	LAMP2_HUMAN	Affects Response To Substance	[76]
Peroxiredoxin-2 (PRDX2)	OTLWCY9T	PRDX2_HUMAN	Affects Response To Substance	[76]
Hemicentin-1 (HMCN1)	OTLZAS0P	HMCN1_HUMAN	Increases Response To Substance	[79]
Furin (FURIN)	OTM2665Z	FURIN_HUMAN	Decreases Response To Substance	[96]
NADH dehydrogenase iron-sulfur protein 8, mitochondrial (NDUFS8)	OTMEAWKO	NDUS8_HUMAN	Affects Response To Substance	[76]
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8)	OTMFG2YY	ALG8_HUMAN	Affects Response To Substance	[76]
Glutathione S-transferase Mu 5 (GSTM5)	OTMMBFY8	GSTM5_HUMAN	Decreases Response To Substance	[96]
Unconventional myosin-Va (MYO5A)	OTMWLP3E	MYO5A_HUMAN	Increases Response To Substance	[159]
Integral membrane protein 2B (ITM2B)	OTMXEPXB	ITM2B_HUMAN	Affects Response To Substance	[76]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2)	OTMZD4PW	SUCB1_HUMAN	Affects Response To Substance	[76]
Four and a half LIM domains protein 1 (FHL1)	OTN535SU	FHL1_HUMAN	Increases Response To Substance	[159]
L-lactate dehydrogenase A chain (LDHA)	OTN7K4XB	LDHA_HUMAN	Increases Response To Substance	[175]
Proto-oncogene serine/threonine-protein kinase mos (MOS)	OTNMQPFJ	MOS_HUMAN	Increases ADR	[60]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Increases ADR	[60]
Calcium-activated potassium channel subunit alpha-1 (KCNMA1)	OTNYXOZO	KCMA1_HUMAN	Affects Response To Substance	[76]
G-protein coupled receptor 35 (GPR35)	OTO23NRK	GPR35_HUMAN	Decreases Response To Substance	[159]
Histone deacetylase 9 (HDAC9)	OTO8O0LF	HDAC9_HUMAN	Increases Response To Substance	[159]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Response To Substance	[176]
Arginine/serine-rich protein 1 (RSRP1)	OTOAZLCL	RSRP1_HUMAN	Affects Response To Substance	[76]
Malectin (MLEC)	OTOPGRF5	MLEC_HUMAN	Affects Response To Substance	[76]
Oncostatin-M-specific receptor subunit beta (OSMR)	OTORWHPL	OSMR_HUMAN	Increases Response To Substance	[159]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Decreases Response To Substance	[177]
Delta(24)-sterol reductase (DHCR24)	OTP301JW	DHC24_HUMAN	Affects Response To Substance	[76]
Interleukin-13 receptor subunit alpha-2 (IL13RA2)	OTPC2G0X	I13R2_HUMAN	Affects Response To Substance	[76]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[76]
Prostaglandin E synthase 3 (PTGES3)	OTPPQWI0	TEBP_HUMAN	Affects Response To Substance	[76]
Large ribosomal subunit protein uL23 (RPL23A)	OTPYLCCX	RL23A_HUMAN	Decreases Response To Substance	[96]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Increases Response To Substance	[96]
Eukaryotic translation initiation factor 5A-1 (EIF5A)	OTQ8DJX5	IF5A1_HUMAN	Increases Response To Substance	[159]
Membrane cofactor protein (CD46)	OTQ8NWJD	MCP_HUMAN	Increases Response To Substance	[96]
Glutamine--fructose-6-phosphate aminotransferase 1 (GFPT1)	OTQBDO45	GFPT1_HUMAN	Decreases Response To Substance	[159]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Decreases Response To Substance	[178]
MAPK/MAK/MRK overlapping kinase (MOK)	OTQK7M9V	MOK_HUMAN	Affects Response To Substance	[76]
Keratin, type I cytoskeletal 23 (KRT23)	OTQW6UAG	K1C23_HUMAN	Increases Response To Substance	[79]
Fibroblast growth factor 5 (FGF5)	OTQXGHBY	FGF5_HUMAN	Affects Response To Substance	[76]
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Affects Response To Substance	[76]
Nuclear body protein SP140 (SP140)	OTQZHFMT	SP140_HUMAN	Affects Response To Substance	[76]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI)	OTR443C5	BGH3_HUMAN	Decreases Response To Substance	[79]
E3 ubiquitin-protein ligase CHFR (CHFR)	OTRAD2TT	CHFR_HUMAN	Decreases Response To Substance	[179]
Large ribosomal subunit protein mL63 (MRPL57)	OTRB659E	RT63_HUMAN	Affects Response To Substance	[76]
Protein CREG1 (CREG1)	OTRHJ8HK	CREG1_HUMAN	Affects Response To Substance	[76]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A)	OTRHPFO2	AN32A_HUMAN	Affects Response To Substance	[76]
Retinol-binding protein 1 (RBP1)	OTRP1MFC	RET1_HUMAN	Increases Response To Substance	[159]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Response To Substance	[159]
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Increases Response To Substance	[159]
Arrestin-C (ARR3)	OTRZ00CH	ARRC_HUMAN	Decreases Response To Substance	[96]
MHC class I polypeptide-related sequence B (MICB)	OTS2DVDW	MICB_HUMAN	Increases Response To Substance	[159]
Latent-transforming growth factor beta-binding protein 2 (LTBP2)	OTS88GSD	LTBP2_HUMAN	Affects Response To Substance	[76]
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B)	OTS9YK3E	KCC2B_HUMAN	Affects Response To Substance	[76]
Lumican (LUM)	OTSRC874	LUM_HUMAN	Decreases Response To Substance	[79]
Rhotekin (RTKN)	OTSS8XR6	RTKN_HUMAN	Decreases Response To Substance	[180]
3-phosphoinositide-dependent protein kinase 1 (PDPK1)	OTT09ZVP	PDPK1_HUMAN	Decreases Response To Substance	[62]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Affects Response To Substance	[76]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Decreases Response To Substance	[79]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)	OTT5JX1F	LITAF_HUMAN	Affects Response To Substance	[76]
Nucleophosmin (NPM1)	OTTBYYT0	NPM_HUMAN	Decreases Response To Substance	[63]
Amyloid beta precursor like protein 2 (APLP2)	OTTFE53M	APLP2_HUMAN	Affects Response To Substance	[76]
Collagen alpha-1(XV) chain (COL15A1)	OTTFKK18	COFA1_HUMAN	Decreases Response To Substance	[79]
Fascin (FSCN1)	OTTGIHTM	FSCN1_HUMAN	Increases Response To Substance	[159]
Keratin, type I cytoskeletal 13 (KRT13)	OTTYSKGX	K1C13_HUMAN	Decreases Response To Substance	[96]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Decreases Response To Substance	[181]
C-X-C chemokine receptor type 4 (CXCR4)	OTUFSBX2	CXCR4_HUMAN	Decreases Response To Substance	[96]
N-acetylgalactosaminyltransferase 7 (GALNT7)	OTUJSCAO	GALT7_HUMAN	Affects Response To Substance	[76]
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (DAD1)	OTUUNQBT	DAD1_HUMAN	Increases ADR	[60]
Mitochondrial Rho GTPase 2 (RHOT2)	OTV8WT2L	MIRO2_HUMAN	Affects Response To Substance	[76]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Decreases Response To Substance	[79]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Response To Substance	[78]
Integrin beta-1-binding protein 1 (ITGB1BP1)	OTVQFNGS	ITBP1_HUMAN	Affects Response To Substance	[76]
U2 small nuclear ribonucleoprotein A' (SNRPA1)	OTWJZFAP	RU2A_HUMAN	Affects Response To Substance	[76]
Decorin (DCN)	OTWLJL7K	PGS2_HUMAN	Decreases Response To Substance	[79]
Glypican-3 (GPC3)	OTWS8WSW	GPC3_HUMAN	Increases Response To Substance	[79]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Response To Substance	[182]
Transmembrane protein 59 (TMEM59)	OTX4EKES	TMM59_HUMAN	Affects Response To Substance	[76]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15)	OTX8SZOT	NUD15_HUMAN	Affects Response To Substance	[76]
Metallothionein-1E (MT1E)	OTXJKU4Y	MT1E_HUMAN	Increases Response To Substance	[96]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3)	OTXL10N9	NDUA3_HUMAN	Affects Response To Substance	[76]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Affects Response To Substance	[165]
Neuroendocrine protein 7B2 (SCG5)	OTXSJMT1	7B2_HUMAN	Affects Response To Substance	[76]
Peripheral myelin protein 22 (PMP22)	OTXWYWCZ	PMP22_HUMAN	Decreases Response To Substance	[96]
Collagen alpha-2(I) chain (COL1A2)	OTY7G382	CO1A2_HUMAN	Increases Response To Substance	[79]
Bone morphogenetic protein 7 (BMP7)	OTYATP2K	BMP7_HUMAN	Increases Response To Substance	[96]
Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PPP1CB)	OTYFTYFR	PP1B_HUMAN	Affects Response To Substance	[76]
Ferritin light chain (FTL)	OTYQA8A6	FRIL_HUMAN	Decreases Response To Substance	[96]
Proteasome subunit beta type-1 (PSMB1)	OTYRFBAH	PSB1_HUMAN	Affects Response To Substance	[76]
Procathepsin L (CTSL)	OTYTUW29	CATL1_HUMAN	Increases Response To Substance	[96]
ADP-ribosylation factor 3 (ARF3)	OTYYQX85	ARF3_HUMAN	Affects Response To Substance	[76]
V-type proton ATPase catalytic subunit A (ATP6V1A)	OTYZ2S9E	VATA_HUMAN	Affects Response To Substance	[76]
Mitochondrial import inner membrane translocase subunit Tim13 (TIMM13)	OTYZQJD3	TIM13_HUMAN	Affects Response To Substance	[76]
Erythropoietin (EPO)	OTZ90CN4	EPO_HUMAN	Decreases Response To Substance	[183]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Affects Response To Substance	[76]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Affects Response To Substance	[76]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Affects Response To Substance	[76]

References

• [1] ClinicalTrials.gov (NCT00100789) S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
• [2] Gemcitabine FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
• [5] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [6] Paclitaxel FDA Label
• [7] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [8] Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
• [9] Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology. 2010;10(1):19-26. doi: 10.1159/000264680. Epub 2010 Mar 19.
• [10] XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas. 2006 Apr;32(3):288-96. doi: 10.1097/01.mpa.0000218314.67111.fb.
• [11] Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.
• [12] 14-3-3 regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
• [15] Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
• [16] Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
• [17] Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
• [18] Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
• [19] Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
• [20] Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
• [21] Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicol Appl Pharmacol. 2022 Feb 15;437:115887. doi: 10.1016/j.taap.2022.115887. Epub 2022 Jan 19.
• [22] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [23] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [24] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [25] Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011 Jan;19(1):188-95.
• [26] Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. Cancer Biol Ther. 2006 Oct;5(10):1294-303. doi: 10.4161/cbt.5.10.3152. Epub 2006 Oct 4.
• [27] Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting -catenin signaling pathway. Chem Biol Interact. 2024 Jan 5;387:110816. doi: 10.1016/j.cbi.2023.110816. Epub 2023 Nov 22.
• [28] p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006 Jan 1;12(1):235-41. doi: 10.1158/1078-0432.CCR-05-1700.
• [29] The anthelmintic drug niclosamide induces GSK--mediated -catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death Dis. 2022 Feb 3;13(2):112. doi: 10.1038/s41419-022-04573-7.
• [30] High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
• [31] CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-B signaling pathway. Cell Biol Toxicol. 2023 Aug;39(4):1549-1560. doi: 10.1007/s10565-022-09746-w. Epub 2022 Aug 1.
• [32] Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007 May 17;26(23):3431-9. doi: 10.1038/sj.onc.1210129. Epub 2006 Dec 4.
• [33] Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 2009 Feb;103(3):384-90. doi: 10.1111/j.1464-410X.2008.08098.x. Epub 2008 Oct 24.
• [34] Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage. J Appl Toxicol. 2023 Oct;43(10):1522-1532. doi: 10.1002/jat.4494. Epub 2023 May 16.
• [35] Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
• [36] Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs. 2007 Feb;18(2):179-85. doi: 10.1097/CAD.0b013e328010ef47.
• [37] Reversible epigenetic regulation of 14-3-3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4.
• [38] Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
• [39] EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One. 2012;7(2):e31067. doi: 10.1371/journal.pone.0031067. Epub 2012 Feb 13.
• [40] Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther. 2002 Nov;1(13):1221-7.
• [41] Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2004 Mar 26;316(1):71-7. doi: 10.1016/j.bbrc.2004.02.017.
• [42] Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol. 2006 Mar 14;12(10):1597-602. doi: 10.3748/wjg.v12.i10.1597.
• [43] Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004 Mar 20;109(2):182-8. doi: 10.1002/ijc.11679.
• [44] Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacol Sin. 2010 Jun;31(6):741-5. doi: 10.1038/aps.2010.54.
• [45] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [46] RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92. doi: 10.1016/j.bbrc.2003.10.060.
• [47] RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res. 2005 May 1;11(9):3433-8. doi: 10.1158/1078-0432.CCR-04-1510.
• [48] Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
• [49] Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas. 2006 Apr;32(3):297-305. doi: 10.1097/00006676-200604000-00010.
• [50] Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer. 2005 Jul 25;93(2):233-41. doi: 10.1038/sj.bjc.6602663.
• [51] Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
• [52] Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
• [53] Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clin Cancer Res. 2016 Jan 15;22(2):366-73. doi: 10.1158/1078-0432.CCR-15-0964. Epub 2015 Sep 16.
• [54] Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010 Nov;101(11):2351-60. doi: 10.1111/j.1349-7006.2010.01671.x.
• [55] Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008 Jul;88(7):773-84. doi: 10.1038/labinvest.2008.40. Epub 2008 May 19.
• [56] Increased expression of transcription factor TFAP2 correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.
• [57] A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba.
• [58] An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone. Biochem Pharmacol. 2007 Jun 15;73(12):1927-38. doi: 10.1016/j.bcp.2007.03.014. Epub 2007 Mar 20.
• [59] Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep;122(3):641-7. doi: 10.1016/j.ygyno.2011.05.003. Epub 2011 Jun 8.
• [60] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [61] Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog. 2014 Sep;53(9):744-52. doi: 10.1002/mc.22026. Epub 2013 May 16.
• [62] Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
• [63] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [64] [Effect of inhibiting the expression of hSMG-1 on chemosensitivity of human non-small cell lung cancer H1299 cells]. Zhonghua Yi Xue Za Zhi. 2011 Mar 1;91(8):554-9.
• [65] A novel 3-dimensional culture system uncovers growth stimulatory actions by TGF in pancreatic cancer cells. Cancer Biol Ther. 2011 Aug 1;12(3):198-207. doi: 10.4161/cbt.12.3.15979. Epub 2011 Aug 1.
• [66] An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007 Jun;12(6):622-30. doi: 10.1634/theoncologist.12-6-622.
• [67] GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. PLoS One. 2014 Dec 3;9(12):e114409. doi: 10.1371/journal.pone.0114409. eCollection 2014.
• [68] Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.
• [69] Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
• [70] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [71] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [72] Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res. 2008 May-Jun;28(3A):1593-602.
• [73] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
• [74] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [75] 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006 Jan 8;231(1):49-64. doi: 10.1016/j.canlet.2005.01.018.
• [76] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [77] Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
• [78] Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
• [79] Microarray-based detection and expression analysis of extracellular matrix proteins in drug?resistant ovarian cancer cell lines. Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.
• [80] Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med. 2011 Jan 26;3(67):67ra7. doi: 10.1126/scitranslmed.3001922.
• [81] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [82] Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
• [83] Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
• [84] Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
• [85] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [86] Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
• [87] Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
• [88] MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
• [89] Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
• [90] Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
• [91] Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
• [92] FaDu cell characteristics induced by multidrug resistance. Oncol Rep. 2011 Nov;26(5):1189-95. doi: 10.3892/or.2011.1418. Epub 2011 Aug 10.
• [93] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [94] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [95] Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004 Nov 15;64(22):8397-404. doi: 10.1158/0008-5472.CAN-04-1612.
• [96] cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
• [97] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [98] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [99] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [100] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [101] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [102] CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
• [103] A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN). Endocrinology. 2004 Apr;145(4):1860-9.
• [104] The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 2005 May;19(5):1170-80.
• [105] Paclitaxel inhibits N-acetyltransferase activity and gene expression in human stomach tumor cells (SC-M1). Res Commun Mol Pathol Pharmacol. 2004;115-116:21-38.
• [106] Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol. 2009 Jun 16;53(24):2298-305.
• [107] Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32.
• [108] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [109] Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
• [110] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [111] Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells. Chem Res Toxicol. 2019 Feb 18;32(2):255-264. doi: 10.1021/acs.chemrestox.8b00269. Epub 2019 Jan 22.
• [112] Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
• [113] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [114] Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005 Jul;4(7):716-9. doi: 10.4161/cbt.4.7.1782. Epub 2005 Jul 2.
• [115] Regulation of retinoschisin secretion in Weri-Rb1 cells by the F-actin and microtubule cytoskeleton. PLoS One. 2011;6(6):e20707. doi: 10.1371/journal.pone.0020707. Epub 2011 Jun 27.
• [116] Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression. Environ Toxicol. 2021 Nov;36(11):2206-2216. doi: 10.1002/tox.23334. Epub 2021 Jul 16.
• [117] CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
• [118] Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Chem Biol Interact. 2020 Jan 5;315:108865. doi: 10.1016/j.cbi.2019.108865. Epub 2019 Oct 16.
• [119] The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
• [120] The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol. 2009 May;25(5):287-93. doi: 10.1080/09513590802530924.
• [121] Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int. 2003 Apr;42(5):419-29. doi: 10.1016/s0197-0186(02)00132-8.
• [122] Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
• [123] Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 7;25(3):94-102. doi: 10.1016/j.cyto.2003.10.004.
• [124] Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother. 2003 Mar;52(3):185-93. doi: 10.1007/s00262-002-0357-4. Epub 2003 Feb 7.
• [125] pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
• [126] Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
• [127] Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol. 2014 May;29(7):804-13. doi: 10.1002/tox.21809. Epub 2012 Aug 21.
• [128] ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol. 2004 Jun;24(6):1499-504.
• [129] Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem. 1999 Mar 19;274(12):8208-16. doi: 10.1074/jbc.274.12.8208.
• [130] Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
• [131] Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
• [132] Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation. J Biochem Mol Toxicol. 2023 May;37(5):e23313. doi: 10.1002/jbt.23313. Epub 2023 Jan 22.
• [133] Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
• [134] Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
• [135] Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res. 2003 Jun;9(6):2366-73.
• [136] Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999 Jul;5(7):1876-83.
• [137] Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway. Breast Cancer Res Treat. 2011 Jul;128(1):57-68. doi: 10.1007/s10549-010-1076-8. Epub 2010 Jul 28.
• [138] Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008 Feb;13(2):259-71. doi: 10.1007/s10495-007-0165-6.
• [139] Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
• [140] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [141] Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci. 2010 May;115(1):118-30. doi: 10.1093/toxsci/kfq028. Epub 2010 Jan 27.
• [142] Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res. 2005 Sep;23(5):988-94. doi: 10.1016/j.orthres.2005.01.018. Epub 2005 Apr 25.
• [143] Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol. 2001 Feb;59(2):254-62. doi: 10.1124/mol.59.2.254.
• [144] Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):55-62. doi: 10.1016/j.taap.2005.06.020. Epub 2005 Jul 26.
• [145] Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol. 2005 Jul 1;70(1):13-21. doi: 10.1016/j.bcp.2005.04.017.
• [146] Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.
• [147] PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol. 2009 Apr 15;77(8):1348-57. doi: 10.1016/j.bcp.2009.01.008. Epub 2009 Jan 24.
• [148] Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 1997;2(5):463-70. doi: 10.1023/a:1026422111457.
• [149] Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs. 2001 Nov;12(10):797-800. doi: 10.1097/00001813-200111000-00002.
• [150] Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
• [151] Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.
• [152] Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
• [153] Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
• [154] 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. Int J Clin Oncol. 2001 Jun;6(3):128-31. doi: 10.1007/pl00012094.
• [155] Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther. 2006 Apr;5(4):380-5. doi: 10.4161/cbt.5.4.2477. Epub 2006 Apr 4.
• [156] MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene. 2004 Sep 29;340(1):53-9. doi: 10.1016/j.gene.2004.06.013.
• [157] Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
• [158] High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010 Jul 1;70(13):5486-96. doi: 10.1158/0008-5472.CAN-10-0713. Epub 2010 Jun 8.
• [159] Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
• [160] E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
• [161] [Correlation of sorcin overexpression to multidrug resistance of human gastric cancer cell line SGC7901]. Ai Zheng. 2008 Apr;27(4):337-42.
• [162] Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
• [163] CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
• [164] Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. doi: 10.1007/s11095-006-0136-6. Epub 2006 Jun 8.
• [165] Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
• [166] Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology. 2016 Jul 15;365:48-58. doi: 10.1016/j.tox.2016.07.016. Epub 2016 Jul 27.
• [167] CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010 Dec;30(12):4791-8.
• [168] CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mllerian tumor). Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.
• [169] ATF3 inhibits arsenic-induced malignant transformation of human bronchial epithelial cells by attenuating inflammation. Toxicology. 2021 Aug;460:152890. doi: 10.1016/j.tox.2021.152890. Epub 2021 Aug 6.
• [170] Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006 Dec;5(12):3248-57. doi: 10.1158/1535-7163.MCT-06-0227.
• [171] MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. doi: 10.1002/jbt.23380. Epub 2023 May 3.
• [172] Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells. Anticancer Drugs. 2007 Mar;18(3):333-40. doi: 10.1097/CAD.0b013e328011fd7f.
• [173] Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol. 2011 Nov 15;82(10):1384-90. doi: 10.1016/j.bcp.2011.06.007. Epub 2011 Jun 13.
• [174] Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. Environ Toxicol. 2021 Sep;36(9):1758-1764. doi: 10.1002/tox.23296. Epub 2021 May 28.
• [175] Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011 Mar 24;54(6):1599-612. doi: 10.1021/jm101007q. Epub 2011 Feb 18.
• [176] Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells. Chem Biol Interact. 2015 Jun 25;235:17-26. doi: 10.1016/j.cbi.2015.04.005. Epub 2015 Apr 10.
• [177] Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41. doi: 10.1073/pnas.1934692100. Epub 2003 Sep 16.
• [178] Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005 Jun;124(6):1300-7. doi: 10.1111/j.0022-202X.2005.23720.x.
• [179] Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
• [180] Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004 Nov 18;23(54):8731-42. doi: 10.1038/sj.onc.1208106.
• [181] Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2011 Jun 1;9(6):681-9. doi: 10.6004/jnccn.2011.0056.
• [182] Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
• [183] Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis. 2006 Dec;24(3):525-30. doi: 10.1016/j.nbd.2006.08.014. Epub 2006 Sep 28.